21/02/2025

Gene expression tests are guiding critical treatment decisions in early-stage breast cancer. Using genomic testing for breast cancer recurrence, you can avoid under or over treatment and the life-changing impact these choices can have on woman's life - now and in years to come.

EndoPredict^® is the only second generation gene expression test for breast cancer validated in premenopausal AND postmenopausal women who are lymph node positive or node negative2 - and the first with level of evidence 1A data, for confident treatment decisions.

EndoPredict^® combines three factors – a molecular score, tumor size and nodal status – to give the EPclin Risk Score. The result is more prognostic information than first generation tests and assays that only measure gene expression, or clinical pathological factors alone.

EndoPredict is a second generation test that incorporates more than other tests.

The test has been developed and validated to include genes that predict both early and late recurrence (0-15 years). These improve prognostic value of EndoPredict^® compared with classical prognostic factors and first generation tests.

EndoPredict Breast Cancer Prognostic Test is the most accurate expression test for early-stage breast cancer recurrence to help you make treatment decisions for your eligible ER positive/HER2 negative primary invasive breast cancer patients.